Daily News

OMB’s Grogan Downplays Drug Price Executive Order, Open To Revisiting Biosimilars-Pay Policy

November 14, 2017
Joe Grogan, the White House Office of Management and Budget’s point person on drug policy, intimated Tuesday (Nov. 14) that there is no drug price executive order in the works and said CMS’ recent biosimilar billing code policy could be re-reversed. He also criticized the 340B hospital drug discount program and said the administration plans to do more work on drug prices, but he dodged questions about drug imports and Medicare price negotiation. Last summer, a draft executive order on...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, news from FDA and much more.